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Objectives: Visfatin, also known as nicotiamide phosphoribosyltransferase or pre-B cell colony enhancing factor, 
is a pro-inflammatory cytokine whose serum level is increased in various cancers. In this study, we investigated 
whether plasma visfatin levels were altered in patients with oral squamous cell carcinoma (OSCC). The relation-
ship between plasma visfatin levels and the pretreatment hematologic profile was also explored.
Study Design: Plasma visfatin concentrations were measured through ELISA in OSCC patients and control sub-
jects. A total of 51 patients with OSCC and 57 age- and body mass index (BMI)-matched control subjects were 
studied. All study subjects were male. 
Results: Plasma visfatin was found to be elevated in patients with OSCC (7.0 ± 4.5 vs. 4.8 ± 1.9 ng/ml, p = 0.002). 
Multiple logistic regression analysis revealed visfatin as an independent association factor for OSCC, even after 
full adjustment of known biomarkers. Visfatin level was significantly correlated with white blood cell (WBC) 
count, neutrophil count, and hematocrit (all p < 0.05). In addition, WBC count, neutrophil count, and visfatin 
gradually increased with stage progression, and hematocrit gradually decreased with stage progression (all p < 
0.05). 
Yu-Duan T, Chao-Ping W, Chih-Yu C, Li-Wen L, Tsun-Mei L, Chia-
Chang H, Fu-Mei C, Hsien-Chang L, Hsia-Fen H, Yau-Jiunn L, Jer-Yiing 
H. Elevated plasma level of visfatin/pre-b cell colony-enhancing factor 
in male oral squamous cell carcinoma patients. Med Oral Patol Oral Cir 
Bucal. 2013 Mar 1;18 (2):e180-6.   
 http://www.medicinaoral.com/medoralfree01/v18i2/medoralv18i2p180.pdf
Article Number: 18574          http://www.medicinaoral.com/
© Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946
eMail:  medicina@medicinaoral.com 
Indexed in: 
Science Citation Index Expanded
Journal Citation Reports
Index Medicus, MEDLINE, PubMed




Med Oral Patol Oral Cir Bucal. 2013 Mar 1;18 (2):e180-6.                                                                                                                                                                        Visfatin/PBEF and oral cancer
e181
Introduction
Oral cancer is the most common malignancy observed in 
the head and neck area. In more than 90% of cases, oral 
cancer is characterized by oral squamous cell carcinoma 
(OSCC) (1). The high prevalence of OSCC in Asia may be 
due to the existence of certain lifestyle factors such as the 
chewing of betel quid together with or without tobacco, 
alcohol consumption, cigarette smoking, infection with 
human papilloma virus and inadequate oral hygiene (2-4). 
In addition, inflammatory cytokines may play an impor-
tant role (5). Chronic inflammation has been causally 
associated with various types of cancer (6,7). Numerous 
studies have reported that the inflammatory infiltrate can 
be a strong risk factor for cancer development in chronic, 
inflammatory conditions. Adipose tissue produces several 
proteins (adipocytokines), such as TNF-alpha, IL-6, type-1 
plasminogen activator inhibitor (PAI-1), adiponectin, lep-
tin, resistin, visfatin and apelin are associated with the risk 
of cancer at various sites (e.g., breast, prostate gland, en-
dometrium and colorectum) (8-11). The altered secretion 
of metabolically active, proinflammatory adipocytokines 
from adipose tissue is believed to play a key role in the 
mechanisms related cancer (12). 
Visfatin has been proposed as being expressed in normal, 
inflamed, and tumor tissues (13,14). It possesses nicoti-
namide adenine dinucleotide (NAD) biosynthetic activ-
ity and regulates growth, apoptosis, and angiogenesis in 
mammalian cells (15,16). Visfatin was originally iden-
tified as a pre-B-cell colony-enhancing factor and was 
thought to play roles in immune response and inflamma-
tion (17-19). Thus, there is some evidence to suggest that 
visfatin activates proinflammatory cytokines in human 
monocytes (20). Additionally, serum visfatin concentra-
tion is increased in patients with sepsis, chronic kidney 
disease and cancer (8,21,22), which indicates that visfatin 
plays a pro-inflammatory role in peripheral tissues. How-
ever, until now, data regarding the role of visfatin and the 
association between visfatin and hematologic profile in 
patients with OSCC is relatively limited. To investigate 
the role of visfatin in OSCC, we measured pretreatment 
plasma visfatin level as well as pretreatment hematologic 
profile in a Chinese population with OSCC.
Subject and Methods
-Patients 
A total of 51 consecutive male subjects with histologi-
cally proven OSCC were enrolled in this prospective 
Parameters OSCC Controls p-value
No 51 57  
Age (years) 52.6?10.1 53.1?7.0 0.780 
BMI (kg/m2) 24.3?3.9 24.8?2.7 0.444 
Systolic BP (mmHg) 131?19 127?17 0.272 
Diastolic BP (mmHg) 79?9.9 80?11 0.421 
Personal habits (n, %)    
None
Only betel quid chewing 
Only alcohol 
Only smoking 
















Betel quid chewing+smoking  8(15.7) 1(1.8) 0.009 
Alcohol+smoking







Tumor site (n, %)    
   Buccal mucosa 26(51.0) -  
   Tongue 8(15.7) -  
   Retromolar 5(9.8) -  
   Lip 2(3.9) -  
   Palate 4(7.8) -  
   Oral floor 6(11.8) -  
Clinical stage (n, %)    
Stage I/II 17(33.3) -  
Stage III/IV 34(66.7) -  
Pathologic T stage (n, %)    
   T1 and T2 23(45.1) -  
   T3 and T4 28(54.9) -  
Lymph-node metastasis (n, %)    
N0 27(52.9) -  
N1+N2 24(47.1) -  
Table 1. Demographic characteristics of the participants.
Data are expressed as mean ± SD or frequency (percent). Com-
parisons were performed by using unpaired t test or chi-square 
test when appropriate. OSCC, oral squamous cell carcinoma.
Conclusion: Increased plasma visfatin levels were associated with OSCC, independent of risk factors, and were cor-
related with inflammatory biomarkers. These data suggest that visfatin may act through inflammatory reactions to 
play an important role in the pathogenesis of OSCC.
Key words: Visfatin; oral squamous cell carcinomas; white blood cell count; neutrophil count.
study (Table 1). All of the subjects were hospitalized for 
examination and treatment. The patients ranged in age 
from 33 to 89 years old (mean 53 years). The primary 
sites of cancer were buccal mucosa (26 cases), tongue 
(8 cases), retromolar (5 cases), lip (2 cases), palate (4 
cases), and floor of the mouth (6 cases).
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A TNM classification was made in accordance with the 
criteria for oral cancer tumors of the American Joint 
Committee on Cancer (AJCC) staging system (sixth 
edition) (23). Regarding the T-stage, 6 cases (11.8%) 
were classified as T1, 17 (33.3%) as T2, 9 (17.7%) as 
T3, and 19 (37.3%) as T4. Regarding N-stage, 27 cases 
(52.9%) had no cervical lymph node metastasis (N0), 
and 10 (19.6%) and 14 (27.5%) cases were classified as 
N1 and N2, respectively. Regarding M-stage, 50 cases 
(98.0%) not spread to distant parts of the body (M0), 
and 1 case (2%) was classified as M1.
Histopathologic evaluation was performed using a he-
matoxylin and eosin-stained preparations from the pre-
treatment biopsy specimens by 2 of the authors (H-C 
L and Y-T L), who were unaware of which patients the 
specimens came from. The degree of histologic differ-
entiation was determined in accordance with the WHO 
criteria published in 1997: 5 cases (9.8%) had grade 1 can-
cer, 12 cases (23.5%) had grade 2 cancer, 5 cases (9.8%) 
had grade 3, and 29 cases (56.9%) had grade 4 cancer. 
Regarding the treatment modality, 44 patients (86.3%) 
underwent surgery. Of the remaining 7 patients, 1 was 
treated with radiation therapy and 6 with chemotherapy. 
Fifty-seven healthy age- and BMI-matched volunteers 
were recruited as control subjects. The control subjects 
ranged in age from 44 to 76 years, with a mean age of 
53 years (Table 1). All of the patients and control sub-
jects were Taiwanese (single race). All study subjects 
were male. None of the patients or control subjects had a 
history of autoimmune diseases or hepatitis. This study 
was approved by the Human Research Ethics Commit-
tee of our hospital, and written informed consent was 
obtained from each participant before enrollment.
Each subject was interviewed in person to obtain de-
mographic information, and information on occupation, 
betel quid chewing, smoking history, alcohol drinking 
habit, and personal and family history of various can-
cers. Detailed information was obtained regarding each 
subject’s betel quid chewing, cigarette smoking, and al-
cohol drinking habits; we specifically queried at what 
age the habits began, what the average daily consump-
tion quantity was, and at what age the habits stopped. 
Plasma biochemical parameters were also measured 
after overnight fasting including triglycerides, total 
cholesterol, creatinine, and glucose, which were meas-
ured by standard commercial methods on a parallel, 
multichannel analyzer (Hitachi7170A, Tokyo, Japan) 
as our previous reports (24). Peripheral complete blood 
cell count was determined by an automated cell counter 
(XE-2100 Hematology Alpha Transportation System, 
Sysmex Corporation, Kobe, Japan). To minimize the 
confounding effect of infection, subjects with a WBC 
count below 4.0 Χ 109/l or greater than 10.0Χ 109/l were 
re-checked and studied extensively to rule out the exist-
ence of chronic infections.
-Plasma visfatin measurement
All of the blood samples were drawn after overnight fast-
ing and plasma samples were kept at -80°C for subse-
quent assay. The concentrations of plasma visfatin were 
determined by commercial enzyme immunoassay kits 
(Phoenix Pharmaceuticals, Belmont, CA). The intraassay 
coefficients of variation were 2.4-2.7% for visfatin. Sam-
ples were measured in duplicate in a single experiment.
-Statistical analyses
The data are shown as the mean ± SD. All of the statis-
tical analyses were performed using the SAS software 
(release 8.0; SAS Institute, Cary, NC). The unpaired 
Student’s t-test was used for between-group compari-
sons for continuous variables, and the χ2 test was used 
for categorical variables. One-way analysis of variance 
was performed to examine the prevalence of each vari-
able between tumor stage groups. Because the distribu-
tions of plasma visfatin, triglyceride, SGOT, SGPT, and 
hematocrit values were skewed, logarithmically trans-
formed values were used for statistical analysis.
The association of visfatin with diabetes was examined by 
multivariate logistic regression analysis that contained: 
1) visfatin, age, and BMI; 2) visfatin, age, BMI, systo-
lic blood pressure (SBP), and diastolic blood pressure 
(DBP); 3) visfatin, age, BMI, SBP, DBP, total cholesterol, 
and triglyceride; 4) visfatin, age, BMI, SBP, DBP, total 
cholesterol, triglyceride, betel quid chewing, drinking, 
smoking status. Multivariate adjusted ORs are presented 
with 95% confidence interval (CI). Pearson’s correlation 
analyses were used to examine the correlation between 
plasma concentrations of visfatin and the values of other 
biomarkers. All of the statistical analyses were two sided, 
and P < 0.05 was considered significant.
Results
The demographic characteristics of our subjects are 
shown in table 1. Patients with OSCC had a significantly 
higher betel quid chewing accompanied with smoking 
and drinking and betel quid chewing accompanied with 
smoking rates, and lower non-personal habits (betel 
quid chewing, smoking, and drinking), and only drink-
ing, and only smoking rates than control subjects. The 
biochemical characteristics of the study subjects are 
shown in table 2. Plasma visfatin levels were found to 
be elevated in patients with OSCC (7.0 ± 4.5 vs. 4.8 ± 
1.9 ng/ml, P = 0.002). Patients with OSCC had signifi-
cantly higher fasting glucose, SGOT, WBC, neutrophil 
count, monocyte count, lymphocyte count, and platelet 
count, and lower albumin, hemoglobin, and hematocrit 
levels than those of control subjects. The mean BMI, 
blood pressure, total-cholesterol, triglyceride, SGPT, 
creatinine, total protein, and red blood cell were similar 
in both groups.
Plasma visfatin concentration was significantly associ-
ated with OSCC even after controlling for anthropo-
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       Parameter OSCC Controls p-value 
No 51 57  
Fasting glucose (mg/dl) 117.3?44.4 96.4?8.2 0.001 
T-cholesterol (mg/dl) 188.0?58.2 197.1?32.3 0.336 
Triglyceride (mg/dl)  150.1?93.0 129.9?67.2 0.232 
SGOT (U/L) 38.9?30.0 24.2?11.0 0.001 
SGPT (U/L) 37.4?32.6 31.1?13.0 0.181 
Creatinine (mg/dl) 1.2?0.3 1.2?0.1 0.077 
Albumin (g/dl) 4.1?0.6 4.4?0.2 0.002 
Total protein (g/dl) 7.0?1.0 7.3?0.6 0.067 
White blood cell count (109/l) 8.254?2.082 5.687?1.621 <.0001 
Neutrophil count (109/l) 5543?1907 3179?1006 <.0001 
Monocyte count (109/l) 423?131 319?112 <.0001 
Lymphocyte count (109/l) 2096?749 1816?450 0.029 
Red blood cell (×10 6/?l) 4.99?1.00 5.08?0.50 0.585 
Hemoglobin (g/dL) 14.5?1.5 15.0?1.2 0.035 
Hematocrit (%) 43.3?4.4 69.6?60.6 0.003 
Platelet count (×10 3/?l) 267.4?74.9 232.9?52.9 0.010 
Visfatin (ng/ml) 7.0?4.5 4.8?1.9 0.002 
Table 2. Biochemical characteristics of the study patients.
Data are means ± SD. OSCC, oral squamous cell carcinoma; 
SGOT, serum glutamate oxaloacetate transaminase; SGPT, se-
rum glutamic pyruvic transaminas.
OSCC
Model adjusted for OR 95% CI p-value 
Plasma visfatin    
Age, BMI 1.311 1.095-1.570 0.003 
Age, BMI, SBP, DBP 1.283 1.075-1.531 0.006 
Age, BMI, SBP, DBP, total 
cholesterol, triglyceride 
1.380 1.080-1.762 0.010 
Age, BMI, SBP, DBP, total 
cholesterol, triglyceride, betel quid  
chewing, drinking, smoking status 
1.367 1.030-1.814 0.030 
Table 3. Association of plasma visfatin with oral squamous cell carcinoma in fully adjusted models.
Results of multivariate logistic regression analysis are presented as the OR of being in oral cancer 
status increase in plasma visfatin. OSCC, oral squamous cell carcinoma; BMI, body mass index; SBP, 
systolic blood pressure; DBP, diastolic blood pressure.
metric variables, blood pressure, lipid profile, betel quid 
chewing, drinking, and smoking status (Table 3). Us-
ing Pearson’s correlation analysis, plasma visfatin lev-
els were correlated with WBC count, neutrophil count, 
and hematocrit level (Table 4). Linear contrast analy-
sis was conducted to evaluate the correlation between 
WBC count, neutrophil count, hematocrit, visfatin, and 
tumor stage (Fig. 1). WBC count, neutrophil count, and 
visfatin levels gradually increased with stage progres-
sion (P < 0.01); in contrast, hematocrit level gradually 
decreased with stage progression (P = 0.011).
Discussion
In this study, we demonstrated that plasma visfatin 
concentrations were significantly elevated in a fully ad-
justed model in patients with OSCC. Furthermore, vis-
fatin was gradually increased with stage progression. 
Moreover, we found a significant correlation between 
plasma visfatin and WBC count, neutrophil count, and 
hematocrit levels. To the best of our knowledge, this is 
the first report to describe elevated visfatin plasma con-
centrations in patients with OSCC.
The biological mechanisms involving visfatin in the 
pathogenesis of OSCC are not yet well understood. Vis-
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Fig. 1. Association between white blood cell count (A), neutrophil count (B), hematocrit (C), visfatin (D), and stage progression of oral squamous 










cell Hemoglobin Hematocrit 
Platelet
count Visfatin
WBC count 0.686** 0.944** 0.361** -0.197 0.107 -0.146 0.025 0.513** 0.243* 
Monocyte count 0.581** 0.324** -0.133 0.089 -0.188 -0.128 0.486** 0.130 
Neutrophil count 0.044 -0.290** 0.011 -0.215* -0.153 0.443** 0.280** 
Lymphocyte count 0.219* 0.318** 0.189 0.203* 0.296** 0.014 
Albumin 0.237* 0.288** 0.131 0.070 -0.171 
Red blood cell 0.293** 0.017 0.162 -0.111 
Hemoglobin 0.106 -0.235* -0.188 
Hematocrit -0.194 -0.256** 
Platelet count 0.046 
Visfatin 
Table 4. Pearson correlation coefficients of study variables in subjects studied.
WBC, white blood cell. *: p < 0.05. **: p < 0.01. 
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fatin is expressed not only in adipocytes and in total 
visceral adipose tissue (20,25,26), but also in activated 
immune cells such as neutrophils, macrophages, and 
lymphocytes (17,20,21). Visfatin activates leukocytes 
and induces the production of cytokines such as IL-1 β, 
tumor necrosis factor, and IL-6 (20). Visfatin can there-
fore be regarded as a proinflammatory, immunomodu-
lating, and apoptosis-inhibiting adipocytokine (20). 
Interestingly, in our study, plasma visfatin levels were 
found to be elevated in patients with OSCC and elevated 
plasma visfatin levels were associated with total WBC 
count and neutrophil count. Hence, on the basis of the 
above theories and the results of this study, we propose 
that visfatin should be considered as a marker of inflam-
mation that participates in the process of OSCC.
Chronic inflammatory reactions have been shown in 
tumors, which may be associated with cancer progres-
sion and chemoresistance. A previous study found that 
visfatin was induced by IL-1 in the human pancreatic 
adenocarcinoma Colo 357 cell line (27). In addition, 
hypoxia in the central regions of solid tumors is a lead-
ing cause of angiogenesis, a fundamental determinant 
of cancer progression. Bae et al. (13) demonstrated that 
visfatin expression was associated with expression of 
hypoxia-inducible factor-1a (HIF-1a) protein in breast 
cancer MCF7 cells and breast cancer tissue. Recently, a 
few studies have correlated the expression of visfatin to 
the clinical outcome of cancer patients (8,28,29). Reddy 
et al. (28) showed that levels of visfatin transcript and 
protein were dramatically increased in glioblastoma tis-
sue specimens. Serum levels of visfatin in malignant as-
trocytomas were significantly altered compared to con-
trols. Visfatin expression together with p53 expression 
was associated with shorter survival of glioblastoma 
patients. Nakajima et al. (8) found that visfatin was sig-
nificantly associated with tumor progression in gastric 
cancer, suggesting that visfatin may be a useful biomar-
ker for prediction of gastric cancer progression. In an-
other study (29) was also showed that visfatin levels in 
cancer patients were significantly higher than those of 
controls. Stage progression significantly correlated with 
visfatin level. They concluded visfatin might be a useful 
biomarker of colorectal malignant potential and stage 
progression. In the present study, we found that visfatin 
was associated with OSCC and was gradually increased 
with stage progression in accordance with previous re-
ports (8,29). In addition, our results also show visfatin 
concentrations being negatively correlated with hemat-
ocrit levels. A previous study demonstrates that low he-
matocrit levels correlate with poor survival in a group 
of surgically treated renal cell carcinoma patients (30). 
Therefore, the correlation between visfatin and hemat-
ocrit may provide an explanation for the increased risk 
of OSCC with high visfatin levels.
The limitations of our study include the following: (1) its 
cross-sectional design limits our ability to infer a causal 
relationship between increased plasma visfatin level and 
OSCC; and (2) our analyses are based on single meas-
urements of blood visfatin, which may not reflect the re-
lationship between visfatin levels and OSCC over time. 
It would be interesting to measure the serial changes in 
plasma visfatin concentrations in oral precancerous and 
oral cancer status to further clarify the role of visfatin 
in OSCC. In addition, although we controlled for other 
major cancer risk factors, the existence of unrecognized 
confounding variables is always possible.
In conclusion, this report shows that visfatin plasma 
concentrations were elevated in patients with OSCC in 
our Chinese study population and that there is a pos-
sible close relationship between visfatin and chronic 
inflammation and the development of oral cancer. 
Visfatin may be involved in the complex interactions 
involving the inflammatory or immune response. 
However, a large-scale prospective cohort study is 
necessary to resolve the potential causal relationship 
between visfatin and OSCC.
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